𝔖 Bobbio Scriptorium

✦ LIBER ✦

Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention : Following in the Path of the Selective Estrogen Receptor Modulators

✍ Scribed by Barbara K. Dunn; Anne Ryan

Book ID: 111398685
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 336 KB
Volume: 1155
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.2009.03688.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety profiles of aromatase inhibitors

Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer

✍ Yutaka Yamamoto; Hirotaka Iwase 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 254 KB

[Translational Endocrinology & Metabolis

[Translational Endocrinology & Metabolism] Translational Endocrinology & Metabolism: Breast Cancer Update Volume 3 || 6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer

✍ Robertson, R. Paul 📂 Article 📅 2012 🏛 The Endocrine Society ⚖ 357 KB

The Estimation and Use of Absolute Risk

The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits of Selective Estrogen Receptor Modulators for Preventing Breast Cancer

✍ MITCHELL H. GAIL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

A randomized, phase III trial exploring

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

✍ OC Freedman, E Amir, G Dranitsaris, M Dowsett, DEC Cole, H Kahn… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 461 KB

5027 A randomized, phase III trial explo

5027 A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC)

✍ O. Freedman; E. Amir; G. Dranitsaris; M. Dowsett; D.E.C. Cole; W. Hanna; F. O'Ma 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

5031 Overall response rate (ORR) and cli

5031 Overall response rate (ORR) and clinical benefit (CB) as clinical indicators for the efficacy of sequential Aromatase Inhibitors (AIs) in 3rd line hormonal treatment (HT) for advanced breast cancer (ABC): pooled analysis of phase II studies

✍ V. Vaccaro; E. Bria; F. Cuppone; M. Milella; C. Nisticò; I. Sperduti; D. Giannar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB